Zanubrutinib ( DrugBank: Zanubrutinib )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
300	IgG4-related disease	1
331	Idiopathic multicentric castleman disease	1

300. IgG4-related disease

---

Clinical trials : 36 /  Drugs : 49 - (DrugBank : 22) / Drug target genes : 16 - Drug target pathways : 98

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04602598 (ClinicalTrials.gov)	January 15, 2022	20/10/2020	Zanubrutinib in Patients With IgG4-Related Disease	A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease	IgG4 Related Disease	Drug: Zanubrutinib 80 MG	Matthew C. Baker	Stanford University	Not yet recruiting	18 Years	85 Years	All	10	Phase 2	United States

331. Idiopathic multicentric castleman disease

---

Clinical trials : 33 /  Drugs : 46 - (DrugBank : 25) / Drug target genes : 31 - Drug target pathways : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04743687 (ClinicalTrials.gov)	January 1, 2021	3/2/2021	Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial	The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial	Idiopathic Multicentric Castleman's Disease	Drug: Zanubrutinib	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	China